Protocol Information

If you are interested in learning more about this study, please call or email the contact person below

Title Protocol # 201585: A Phase III, randomized, multicenter, parallel-group, noninferiority,open-label study evaluating the efficacy, safety, and tolerability of switching to long-acting cabotegravir plus longacting rilpivirine from current INI- NNRTI-, or PI-based antiretroviral regimen in HIV-1-infected adults who are virologically suppressed.
Description Study visits will be at Erie County Medical Center
Objective Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
Principal Investigator SHON, ALYSSA
Age Group Adult
Drugs Involved
Clinical Trials.gov http://www.clinicaltrials.gov/ct2/show/NCT02951052/
Status Open
Key Eligibility Ages 18 or older
HIV-1
Disease Group HIV/AIDS; Infectious Diseases
Treatment cabotegravir plus long acting rilpivirine
Contact SIBU NAIR
716-898-4119
sibusiva@buffalo.edu